Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.
Richly
H
H
Department of Internal Medicine, University of Essen Medical School, Essen, Germany. heike.richly@uni-due.de
Grubert
M
M
Scheulen
M E
ME
Hilger
R A
RA
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000378:metabolism / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics*; D016903:Drug Monitoring; D006207:Half-Life; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D007962:Leukocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D012720:Severity of Illness Index
D000903:Antibiotics, Antineoplastic; C074869:7-deoxy-13-dihydroadriamycinone; D004317:Doxorubicin